Sorcero Raises $42.5M Series B to Expand AI Platform Across Life Sciences
Sorcero, the Washington, D.C.–based AI‑powered intelligence platform serving the life sciences industry, has announced a major $42.5 million Series B funding round to accelerate its global expansion and scale its technology for pharmaceutical, biotech, and medical device companies. The financing, closed in November 2025, brings the company’s total capital raised to approximately $59 million since its founding in 2018.
The Series B round was led by NewSpring Growth (lead investor), the growth equity strategy of NewSpring Capital focused on high‑growth, transformative technology firms. Joining the round were Leawood Venture Capital and Blu Ventures, both of which contributed to the new capital alongside the lead investor. This infusion of funding is expected to support Sorcero’s continued development of its medically‑tuned, regulatory‑compliant AI platform that extracts actionable insights from vast volumes of scientific and medical data.
Sorcero’s technology — often described as an agentic AI platform — is used by life sciences organizations to accelerate insight generation across critical functions such as medical affairs, safety, scientific communications, and market intelligence. According to the company, its platform is already adopted by one‑third of the top 30 global pharmaceutical firms, helping these customers improve productivity in scientific evidence generation by as much as 92 % and delivering manuscripts or value dossiers months faster than traditional manual methods.
CEO and co‑founder Dipanwita Das emphasized the strategic role of the funding in scaling Sorcero’s capabilities, noting that the company aims to pioneer a “unified intelligence platform” for the precision medicine era. By harnessing AI tailored to the life sciences domain, Sorcero positions itself to help organizations manage complex medical data, personalize engagement with healthcare professionals, and support broader adoption of advanced therapies.
Industry observers point to market conditions that make Sorcero’s offering particularly relevant. Precision medicine and specialty drugs now account for more than 80 % of newly approved therapies, but many breakthrough treatments struggle to secure rapid adoption and coverage. Sorcero’s platform integrates hundreds of data sources — from published literature and congress proceedings to real‑world evidence and safety records — to provide a comprehensive, 360‑degree view of healthcare professionals and scientific insights essential for evidence‑based engagement.
The capital raised in this round will be used to accelerate Sorcero’s global expansion into new market segments, including medical device analytics, while continuing to scale its core platform for existing life sciences use cases. The company has also strengthened its offerings via strategic partnerships and recent acquisitions: for example, Sorcero acquired Axiom Health, a real‑world data platform, enabling the launch of Sorcero MedTech and expanding its reach across pharmaceutical and medical device markets.
Sorcero’s journey to this funding milestone reflects a steady progression in both technological sophistication and investor confidence. Earlier funding rounds include a $10 million Series A in 2021 led by CityRock Venture Partners and Harmonix Fund, with participation from several other venture investors, which supported the initial scaling of its language intelligence platform.
The company’s growth has also been recognized through several industry accolades. In 2025, Sorcero was named to Fortune’s list of America’s Most Innovative Companies, reflecting its impact on life sciences workflows and its role in enabling faster, more reliable scientific insights through AI.
With its latest financing, Sorcero is poised to further its mission of transforming how life sciences organizations leverage AI to make data‑driven decisions, accelerate patient access to medical innovations, and ultimately improve health outcomes across global markets.
